A consolidated subsidiary, Chongqing Santen Kerui Pharmaceutical Co., Ltd., has filed a petition for commencement of bankruptcy proceedings with the local court. Total liabilities amount to 143 million CNY (approximately 3.3 billion yen). As the Company and its subsidiaries have fully provided allowance for doubtful accounts for the related debts, the impact on the Company’s consolidated results is expected to be minor. Bankruptcy proceedings are expected to proceed with asset disposals and distributions to creditors.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4536","jir_company_name":"Santen Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4536-20261016-01.pdf","jir_short_summary":"A consolidated subsidiary, Chongqing Santen Kerui Pharmaceutical Co., Ltd., has filed a petition for commencement of bankruptcy proceedings with the local court. Total liabilities amount to 143 million CNY (approximately 3.3 billion yen). As the Company and its subsidiaries have fully provided allowance for doubtful accounts for the related debts, the impact on the Company's consolidated results is expected to be minor. Bankruptcy proceedings are expected to proceed with asset disposals and distributions to creditors.","jir_summary":"### Overview of the News\nA consolidated subsidiary of Santen Pharmaceutical Co., Ltd., Chongqing Santen Kerui Pharmaceutical Co., Ltd., resolved to file a petition for commencement of bankruptcy proceedings on local time October 16, 2026. The decision follows changes in the business environment due to regulatory reforms in the Chinese market. Although liquidation was resolved in October 2024, prospects for asset sales and full repayment of liabilities did not materialize, leading to the filing for bankruptcy proceedings.\n\n### Expected Impact and Response\nThe Company holds loans receivable from the subsidiary, but these have been fully provided for as allowance for doubtful accounts; therefore, the impact on the Company's consolidated results for fiscal year 2026 is expected to be minor. Once bankruptcy proceedings advance and the court issues a bankruptcy declaration, assets are expected to be disposed of and distributions made to creditors. The equity valuation of Chongqing Kerui Pharmaceutical has been recorded as 0 yen, and the effect on related parties is limited.","jir_financial_highlights":"Total liabilities: 143 million CNY (Unknown)\nLoans receivable from the Company: 20 hundred million yen (Fully provided for as allowance for doubtful accounts)\nEquity valuation of consolidated subsidiary: 0 yen (Impairment already recorded)\nFuture impact: Minor (Unknown)","jir_category":"","jir_hashtags":"#SantenConsolidatedInformation, #Disclosure, #ImportantNotice","jir_key_figures":"Total liabilities: 143 million CNY (approx. 3.3 billion yen)\nLoans receivable from the Company: 20 hundred million yen\nEquity valuation: 0 yen","jir_meta_title":"Santen Pharmaceutical Co., Ltd. Notice: Filing for Commencement of Bankruptcy Proceedings by Consolidated Subsidiary | October 16, 2026","jir_meta_description":"Chongqing Santen Kerui Pharmaceutical Co., Ltd., a consolidated subsidiary of Santen Pharmaceutical Co., Ltd., has resolved to file for commencement of bankruptcy proceedings. Total liabilities are 143 million CNY (approx. 3.3 billion yen). Impact on the Company is expected to be minor due to allowance for doubtful accounts. We will monitor the progress of the proceedings.","jir_og_title":"Santen Pharmaceutical Co., Ltd. Notice: Filing for Commencement of Bankruptcy Proceedings by Consolidated Subsidiary","jir_og_description":"A consolidated subsidiary of Santen Pharmaceutical Co., Ltd. has filed for commencement of bankruptcy proceedings. Liabilities amount to approx. 3.3 billion yen. The Company's impact is limited; the progress of the proceedings will be monitored.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7842,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-132295","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n